{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
M016
(2023)
Source URL:
First approved in 2019
Source:
M017
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Menopur by Ferring Pharmaceuticals [Canada]
Source URL:
First approved in 2016
Source:
NADA141431
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01339299: Phase 4 Interventional Completed Controlled Ovarian Stimulation
(2009)
Source URL:
First approved in 1975
Source:
BLA021663
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00514813: Phase 4 Interventional Terminated Anemia
(2007)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02131220: Phase 4 Interventional Completed Myocardial Infarction
(2015)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02234869: Phase 4 Interventional Withdrawn Relapsing Multiple Sclerosis
(2014)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
